osimertinib
astrazeneca
['sclc', 'lcsm,(-blcsm)', 'nsclc']
#asco23 day 1 #lcsm #egfrmutant #nsclc css at 1p cdt s406 progress over 2o y neoadjuvant osi again study (tki+/-chemo) met ihc in 2nd line egfr+ drs. sarah goldberg, pasi janne 
Leslye M. Heisler Associate Professor of Lung Cancer Excellence @PennMedicine | AD @PC31 | Incoming Chair @ASCO #CCC | Tweets my own | COI: https://t.co/ghKU8KhBvl